HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism

被引:132
作者
Mottet, D. [1 ,2 ]
Pirotte, S. [1 ]
Lamour, V. [1 ]
Hagedorn, M.
Javerzat, S. [3 ]
Bikfalvi, A. [3 ]
Bellahcene, A. [1 ]
Verdin, E. [2 ]
Castronovo, V. [1 ]
机构
[1] Univ Liege, Metastasis Res Lab, GIGA Canc Ctr Expt Canc Res, B-4000 Liege, Belgium
[2] Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94158 USA
[3] Univ Bordeaux 1, INSERM, U920, European Lab Angiogenesis & Translat Res,Ex E0113, F-33405 Talence, France
关键词
histone deacetylase; p21(WAF1/Cip1); Sp1; siRNA; cancer; HISTONE DEACETYLASE INHIBITORS; TUMOR-SUPPRESSOR PROTEIN; WAF1/CIP1 GENE PROMOTER; IN-VIVO; DNA-BINDING; SP1; SITES; P53; TRANSCRIPTION; ACETYLATION; COLON;
D O I
10.1038/onc.2008.371
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer cells have complex, unique characteristics that distinguish them from normal cells, such as increased growth rates and evasion of anti-proliferative signals. Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptionalreac tivation of the p21(WAF1/Cip1) gene. The HDACs that regulate p21(WAF1/Cip1) are not fully identified. Using small interfering RNAs, we found that HDAC4 participates in the repression of p21(WAF1/Cip1) through Sp1/Sp3-, but not p53-binding sites. HDAC4 interacts with Sp1, binds and reduces histone H3 acetylation at the Sp1/Sp3 binding site-rich p21(WAF1/Cip1) proximal promoter, suggesting a key role for Sp1 in HDAC4-mediated repression of p21(WAF1/Cip1). Induction of p21(WAF1/Cip1) mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.
引用
收藏
页码:243 / 256
页数:14
相关论文
共 73 条
[1]   Rational development of histone deacetylase inhibitors as anticancer agents: A review [J].
Acharya, MR ;
Sparreboom, A ;
Venitz, J ;
Figg, WD .
MOLECULAR PHARMACOLOGY, 2005, 68 (04) :917-932
[2]   p21WAF1 is required for butyrate-mediated growth inhibition of human colon cancer cells [J].
Archer, SY ;
Meng, SF ;
Shei, A ;
Hodin, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (12) :6791-6796
[3]   DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines [J].
Basile, V ;
Mantovani, R ;
Imbriano, C .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (04) :2347-2357
[4]   Anticancer activities of histone deacetylase inhibitors [J].
Bolden, Jessica E. ;
Peart, Melissa J. ;
Johnstone, Ricky W. .
NATURE REVIEWS DRUG DISCOVERY, 2006, 5 (09) :769-784
[5]   Inhibition of histone deacetylase activity by butyrate [J].
Davie, JR .
JOURNAL OF NUTRITION, 2003, 133 (07) :2485S-2493S
[6]   Histone deacetylases (HDACs): characterization of the classical HDAC family [J].
De Ruijter, AJM ;
Van Gennip, AH ;
Caron, HN ;
Kemp, S ;
Van Kuilenburg, ABP .
BIOCHEMICAL JOURNAL, 2003, 370 :737-749
[7]  
Doetzlhofer A, 1999, MOL CELL BIOL, V19, P5504
[8]   Histone deacetylase inhibitors: Overview and perspectives [J].
Dokmanovic, Milos ;
Clarke, Cathy ;
Marks, Paul A. .
MOLECULAR CANCER RESEARCH, 2007, 5 (10) :981-989
[9]   Vorinostat in cutaneous T-CELL lymphoma [J].
Duvic, Madeleine ;
Vu, Jenny .
DRUGS OF TODAY, 2007, 43 (09) :585-599
[10]   Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma [J].
Duvic, Madeleine ;
Vu, Jenny .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (07) :1111-1120